Therapeutic Asset Ratings
395 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Hrs-6208
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
inm176
Prostate Cancer
Milton S. Hershey Medical Center
P1/2
CC
(40)
inr102
Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
P1/2
CC
(40)
Lutetium Dgul
Prostate Cancer
Cellbion Co., Ltd.
P1/2
CC
(40)
Lutetium Lu 177 Jh020002
Prostate Cancer
Bivision Pharmaceuticals, Inc.
P1/2
CC
(40)
mdx2001
Prostate Cancer
ModeX Therapeutics, An OPKO Health Company
P1/2
CC
(40)
Mrt-2359
Prostate Cancer
Monte Rosa Therapeutics, Inc
P1/2
CC
(40)
mt-4561
Prostate Cancer
Tanabe Pharma America, Inc.
P1/2
CC
(40)
Multiple Single Doses Of 225Ac-J591
Prostate Cancer
Weill Medical College of Cornell University
P1/2
CC
(40)
Mva-Pcaq
Prostate Cancer
Barinthus Biotherapeutics
P1/2
CC
(40)
Pocenbrodib
Prostate Cancer
Pathos AI, Inc.
P1/2
CC
(40)
rc48
Prostate Cancer
Tianjin Medical University Second Hospital
P1/2
CC
(40)
Rezatapopt
Prostate Cancer
PMV Pharmaceuticals, Inc
P1/2
CC
(40)
Rifaximin
Prostate Cancer
Mansoura University
P1/2
CC
(40)
SL-28
Prostate Cancer
Second Life Therapeutics
P1/2
CC
(40)
Solnerstotug
Prostate Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(40)
st101
Prostate Cancer
Sapience Therapeutics
P1/2
CC
(40)
SX682
Prostate Cancer
National Cancer Institute (NCI)
P1/2
CC
(40)
Tazemetostat
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
tb511
Prostate Cancer
Twinpig Biolab, Inc.
P1/2
CC
(40)
T-Dxd
Prostate Cancer
AstraZeneca
P1/2
CC
(40)
TIPIRACIL
Prostate Cancer
Parabilis Medicines, Inc.
P1/2
CC
(40)
tng348
Prostate Cancer
Tango Therapeutics, Inc.
P1/2
CC
(40)
Trifluridine
Prostate Cancer
Parabilis Medicines, Inc.
P1/2
CC
(40)
Verteporfin
Prostate Cancer
SpectraCure AB
P1/2
CC
(40)
Showing 251 to 275 of 395 assets
Previous
Page 11 of 16
Next